MacroGenics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 2.38 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 151.61M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Details
| Name | MacroGenics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 293 |
| Founded | 2000 |
| Ipo Date | 2013-10-10 |
| Ceo | Eric Risser |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US5560991094 |
| Cusip | 556099109 |
| Cik | 0001125345 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Eric Blasius Risser | Chief Executive Officer, President and Director |
| James Karrels | Senior Vice President and Chief Financial Officer |
| Dr. Ezio Bonvini M.D. | Senior Vice President of Research and Chief Scientific Officer |
| Dr. Araba Lamouse-Smith Ph.D. | Vice President of Technical Operations |
| Jeffrey Stuart Peters J.D. | Senior Vice President, Corporate Secretary, General Counsel and Corporate Compliance Officer |
| Steve Harig | Senior Vice President of Human Resources |
| Harish Krishnaswamy | Senior Vice President of Business Development and Portfolio Planning |
| Dr. Frank George Perabo FEBU, M.D., Ph.D. | Vice President and Interim Head of Clinical Development |
| Beth Smith | Vice President, Controller and Treasurer |
Contact
| Address | 9704 Medical Center Drive, Rockville, Maryland 20850, United States |
| Phone | 301 251 5172 |
| Website | https://www.macrogenics.com |